Croatia Joins European Medicines Network - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Croatia Joins European Medicines Network


Croatia joined the European Union on July 1, 2013 and, therefore, became part of the European Medicines Network. The country will now be involved in European Medicines Agency (EMA) activities. Europe began preparing for Croatia’s participation in 2007 with the creation of the Instrument for Pre-accession Assistance (IPA) program and with ongoing work with Croatian authorities. Croatia participated in selected EMA meetings as part of the IPA program.

EMA and Croatia also started a pre-accession linguistic review of product information in January 2011 to facilitate “the phasing-in of European Commission decisions on centrally authorised medicines once Croatia joined the EU thereby avoiding delays in the supply of medicines in Croatia.” EMA has issued revised guidance that outlines the phasing-in of authorized products in Croatia and operational aspects. 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here